This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Lilly's Phase 2 results for lepodisiran, which reduced levels of genetically inherited heart disease risk factor, lipoprotein(a).

Ticker(s): LLY

Who's the expert?

Institution: University of Michigan 

  • Interventional Cardiologist and Clinical Scientist at the University of Michigan
  • Manages 100 patients per month for inheritied heart diseases
  • Research focos in exploring the molecular and cellular response to myocardial stress and its role in cardiac remodeling

Interview Goal
This conversation will focus on the current treatment landscape and potential use of lepodisiran for patients at risk of inherited heart disease. 

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.